Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Leerink Partners Reiterates Outperform Rating on Vaxcyte (PCVX)

November 6, 2024 5:59 AM EST

Leerink Partners analyst David Risinger reiterated an Outperform rating and $135.00 price target on Vaxcyte (NASDAQ: PCVX).

The analyst comments "Bottom Line: PCVX reported OpEx of $140M which was +2% or +$3M vs. our est. of $137M. The companys pipeline remains on track; the next readout to watch is VAX-24 Ph2 infant data at the end of 1Q25. We remain bullish on PCVX following competitive PCV pipeline commentary from PFE (MP) and GSK (Not Rated). PFE disclosed on its on... More